**FOI Ref: 6604**

**Category(ies): Clinical - Drugs**

**Subject: Usage of Intra-vitreal Injections or Implants May - August 2022**

**Date Received: 09/09/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| 1. How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from May to August 2022:  * Aflibercept * Bevacizumab * Brolucizumab * Dexamethasone * Faricimab * Ranibizumab - Lucentis * Ranibizumab – Ongavia | Please note the below figures are for May, June and July. The August figures are not yet available.   * Aflibercept – 522 * Bevacizumab – 0 * Brolucizumab – 41 * Dexamethasone – 2 * Faricimab – 0 * Ranibizumab – Lucentis – 626 * Ranibizumab – Ongavia – 0 |
| 1. Please provide the number of injections/implants by eye condition for the four-month period from May to August 2022.  |  |  |  |  | | --- | --- | --- | --- | | **Number of Injections/Implants: May - August 2022**  Please note the below figures are for May, June and July. The August figures are not yet available. | | |  | |  |  |  |  | | **Treatment** | **Eye Conditions** | | | | Wet Age-Related Macular Degeneration (wAMD) | Diabetic Macular Oedema (DMO) | Retinal Vein Occlusion (RVO) | | Aflibercept | 270 | 118 | 132 | | Bevacizumab |  |  |  | | Brolucizumab | 41 |  |  | | Dexamethasone |  |  | 2 | | Faricimab |  |  |  | | Ranibizumab - Lucentis | 362 | 122 | 140 | | Ranibizumab - Ongavia |  |  |  | | |